TALPHERA, INC.

TLPH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-14.3M $-13.0M $-18.4M $47.8M $-35.1M $-40.4M $-53.2M $-47.1M
Depreciation & Amortization $0 $311.0K $1.6M $2.0M $1.9M $1.7M $575.0K
Depreciation $800.0K $1.1M $1.1M $900.0K $500.0K
Amortization
Stock-Based Compensation $699.0K $989.0K $1.7M $2.9M $4.6M $4.4M $5.1M $5.2M
Net Cash from Operating Activities $-11.4M $-12.7M $-17.5M $-28.3M $-30.0M $-38.5M $-51.2M $-29.1M
Investing Activities
Capital Expenditures $0 $100.0K $364.0K $1.8M $1.9M $3.5M $819.0K
Business Acquisitions $0 $1.7M $821.0K
Net Cash from Investing Activities $-14.3M $3.8M $-528.0K $36.5M $-26.1M $34.1M $-36.6M $-10.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $22.7M $12.0M $3.5M $-507.0K $41.5M $17.0M $14.5M $75.0M
Net Change in Cash $-3.0M $3.1M $-14.6M $7.6M $-14.6M $12.6M $-73.3M $35.1M
Free Cash Flow $-12.7M $-17.6M $-28.7M $-31.8M $-40.4M $-54.7M $-29.9M
← Newer Page 1 of 3 Older →